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Respiratory  syncytial  virus  (RSV)  is  the  leading  cause  of  bronchiolitis  and  hospitalisation  of  infants  in
developed  countries.  Surfactant  protein  A (SP-A)  is  an  important  innate  immune  molecule,  localized  in
pulmonary  surfactant.  SP-A  binds  to carbohydrates  on  the  surface  of  pathogens  in a calcium-dependent
manner  to  enable  neutralisation,  agglutination  and  clearance  of pathogens  including  RSV.
SP-A  forms  trimeric  units  and  further  oligomerises  through  interactions  between  its  N-terminal
domains.  Whilst  a recombinant  trimeric  fragment  of  the  closely  related  molecule  (surfactant  protein  D)
has been  shown  to retain  many  of the  native  protein’s  functions,  the importance  of  the SP-A  oligomeric
structure  in  its interaction  with  RSV  has  not  been  determined.
The  aim  of this  study  was  to  produce  a functional  trimeric  recombinant  fragment  of  human  (rfh)SP-A,
which  lacks  the  N-terminal  domain  (and  the  capacity  to oligomerise)  and test its  ability to neutralise  RSV
in  an  in  vitro  model  of  human  bronchial  epithelial  infection.
We  used  a novel  expression  tag  derived  from  spider  silk  proteins  (‘NT’)  to  produce  rfhSP-A  in
Escherichia  coli,  which  we  found  to be trimeric  and  to bind  to  mannan  in  a calcium-dependent  man-
ner.  Trimeric  rfhSP-A  reduced  infection  levels  of human  bronchial  epithelial  (AALEB)  cells  by RSV by up
to  a mean  (±SD)  of  96.4  (±1.9)  % at 5 g/ml,  which  was signiﬁcantly  more  effective  than  dimeric  rfhSP-A
(34.3  (±20.5)  %)  (p  <  0.0001).  Comparatively,  native  human  SP-A  reduced  RSV infection  by  up  to  38.5
(±28.4)  %.
For  the  ﬁrst time  we  report  the  development  of  a  functional  trimeric  rfhSP-A  molecule  which  is  highly
efﬁcacious  in  neutralising  RSV,  despite  lacking  the  N-terminal  domain  and  capacity  to  oligomerise.
© 2016  The  Authors.  Published  by Elsevier  GmbH.  This  is an  open  access  article  under  the  CC  BY. Introduction
RSV is the leading cause of acute childhood lower respiratory
ract infection and a major cause of hospital admissions (Nair et al.,
010). Surfactant protein A (SP-A) is an important innate immune
olecule expressed throughout the human respiratory tract and
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ttp://dx.doi.org/10.1016/j.imbio.2016.10.015
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present in pulmonary surfactant. SP-A is a collectin, which binds to
carbohydrates in a calcium-dependent manner and contains a col-
lagenous region in common with other members of the collectin
family such as both surfactant protein D (SP-D) and the serum col-
lectin, mannan binding lectin (MBL). SP-A functions as an innate
immune defence molecule, which binds to carbohydrates on the
surface of an array of different pathogens, promoting their neu-
tralisation, agglutination and clearance. SP-A has been shown to
neutralise numerous different viruses such as RSV (LeVine et al.,
1999) inﬂuenza A virus (Hartshorn et al., 1997) and HIV (Gaiha et al.,
2008).
le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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SP-A is also an important modulator of the inﬂammatory
mmune response, as previously reviewed (Wright, 2005). SP-A
nhances uptake of apoptotic cells by macrophages and functions to
odulate the production of pro-inﬂammatory mediators in a con-
ext dependent manner (Gardai et al., 2003). SP-A has been shown
o enhance the killing of Klebsiella pneumoniae by macrophages
Kabha et al., 1997), modulate dendritic cell maturation (Brinker
t al., 2003) and inhibit the proliferation and function of T cells
Borron et al., 1996, 2002). SP-A has also been shown to interact
ith various allergens (Malhotra et al., 1993) and prevent the bind-
ng of IgE from asthmatic children to house dust mite (Wang et al.,
996).
The potential importance of SP-A in RSV infection has been illus-
rated by the association of genetic polymorphisms within the SP-A
enes with disease severity (Thomas et al., 2009; Ampuero et al.,
011; Lofgren et al., 2002; El Saleeby et al., 2010). However, the
recise role of SP-A in neutralising RSV infection is not clear. Sftpa1
nock out mice are shown to have increased titres of RSV in their
ungs after infection as compared with wild type mice; treatment of
hese mice with exogenous SP-A enhanced RSV clearance (LeVine
t al., 1999). Contrastingly, human SP-A has been reported to be
xploited by RSV in vitro to provide a route of entry to enhance
nfection of Hep2 cells (Hickling et al., 2000). The importance of
uman SP-A in interacting with and neutralising RSV thus remains
o be fully elucidated.
Human SP-A forms functional heterotrimeric units composed
f Sftpa1 and Sftpa2 gene products (SP-A1 and SP-A2), the compo-
ition of which varies in different disease states (Tagaram et al.,
007). Each SP-A unit is composed of four domains: the functional
rimeric lectin domain also known as the carbohydrate recogni-
ion domain (CRD); the alpha-helical neck domain responsible for
rimerisation; a collagen-like domain and an N-terminal domain
mportant for higher order oligomerisation. SP-A can oligomerise to
orm octadecameric structures, which resemble those of mannose-
inding lectin (MBL). Oligomerisation increases the overall avidity
f binding to polyvalent ligands and the capacity to agglutinate
athogens.
A functional recombinant fragment of human SP-D (rfhSP-D)
as previously been produced. rfhSP-D contains only the CRD, neck
nd a short collagenous stalk but lacks the N-terminal domain and
he majority of the collagen-like domain. This fragment has been
ell characterised, structurally and functionally (Clark et al., 2016).
sing this molecule, it has been demonstrated that the full collagen
omain and N-terminal domain of SP-D are not essential for many
f the natural functions of SP-D. For example, rfhSP-D has been
hown to be effective in neutralising a range of pathogens includ-
ng RSV (Clark, 2010; Hickling et al., 1999). rfhSP-D has also been
hown to be effective in both decreasing allergic inﬂammation and
,3 -glucan mediated neutrophilic inﬂammation and decreasing
he degree of emphysematous change in SP-D−/− mice (Fakih et al.,
015; Clark et al., 2005).
Technical problems have thus far impeded the production of
n equivalent functional trimeric recombinant fragment of human
P-A (rfhSP-A). A recombinant fragment of rat SP-A has been pre-
iously produced (Head et al., 2003). However, the rat Sftpa1 gene
as only a 71% similarity to the human Sftpa1 gene and functional
ifferences between rat and human SP-A have been reported (Allen
t al., 1999).
An equivalent fragment of SP-A would allow characterisation
f the structure of the human SP-A CRD and the importance of the
ligomeric structure for its native functions. Such a fragment would
vercome previous problems associated with the full length SP-A
ith regards to self-aggregation of higher order oligomers medi-
ted through the collagen-like domain (Haagsman et al., 1990).
oreover, it would overcome the requirement for expression ingy 222 (2017) 111–118
eukaryotic systems, which are expensive, and result in relatively
low yields.
The N-terminal domain (NT) from spider silk and proteins
(spidroins) is highly soluble on its own and allows high levels of
soluble expression of spidroins (Kronqvist et al., 2014; Hedhammar
et al., 2008; Rising and Johansson, 2015). This domain may  have
potential in allowing high levels of expression of other target pro-
teins in heterologous systems. In this study, we investigated the
use of NT of the major ampullate spidroin 1 from Euprosthenops
australis as an expression partner to enable the production of a func-
tional rfhSP-A molecule composed of SP-A1 (Rising et al., 2006). We
used a human bronchial epithelial in vitro model to investigate the
capacity of rfhSP-A to neutralise a clinically relevant strain of RSV
as compared with native human (nh)SP-A.
2. Methods
2.1. Puriﬁcation of nhSP-A
nhSP-A was  puriﬁed from bronchoalveolar lavage ﬂuid (BAL)
from human patients with alveolar proteinosis using a butanol
extraction method, as previously described (Wright et al., 1987).
BAL was  collected from patients at the Royal Brompton Hospital
with informed consent and the necessary ethical permission (the
Royal Brompton and Hareﬁeld Research Ethics Committee NRES
10/H0504/9).
2.2. Cloning
The Sftpa1 (6A2) gene was cloned from human lung RNA. Eth-
ical permission exists for the use of human lung tissue resected
with informed consent from patients undergoing thoracic surgery
at Southampton General Hospital (Southampton & SW Hants LREC
08/H0502/32). rfhSP-A was cloned into a pET 21a+ expression vec-
tor to include the CRD, neck and 8 x Gly Xaa Yaa repeats of the
collagen stalk. The rfhSP-A gene was optimised for expression in
Escherichia coli and subsequently sub-cloned into a pT7 vector con-
taining the NT tag N-terminally of the rfhSP-A. A His6-tag was
included N-terminally of NT to allow efﬁcient puriﬁcation and a
thrombin cleavage site to allow removal of the NT tag after puriﬁ-
cation (Supplementary Fig. 1).
2.3. Expression of NT-rfhSP-A and isolation of inclusion bodies
BL21 (DE3) E. coli containing the plasmid encoding rfhSP-A
or NT-rfhSP-A were grown in LB media containing appropriate
antibiotics. Expression was induced by addition of IPTG (ﬁnal con-
centration of 0.5 mM)  and protein was expressed for 16 h at 30 ◦C.
After lysis, inclusion bodies were isolated by centrifugation at
27,000 x g, 4 ◦C for 1 h and washed by suspension in 20 mM Tris
150, mM NaCl, pH 7.4 (TBS) containing 1% triton X-100 with subse-
quent centrifugation. This was  repeated twice with the ﬁnal wash
being in TBS alone.
2.4. Puriﬁcation of NT-rfhSP-A and subsequently rfhSP-A
NT-rfhSP-A was  solubilised in 5 mM CaCl2 and 5% glycerol (v/v),
8 M urea, pH 7.4 (solubilisation buffer) at 4 ◦C, overnight with mix-
ing. NT-rfhSP-A was refolded by dialysis at 4 ◦C for 2 h against
solubilisation buffer but with decreasing concentrations of urea
(4 M,  2 M,  1 M and 0 M).  After removal of precipitate, NT-rfhSP-
A was  puriﬁed using an IMAC puriﬁcation column and cleaved
through incubation with 10 units of thrombin (GE Healthcare) per
mg of protein for 6 h at room temperature. rfhSP-A was  puriﬁed
by reapplication to an IMAC column to remove His-tagged NT.
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T-rfhSP-A and rfhSP-A were analysed by SDS-PAGE under reduc-
ng conditions with subsequent Coomassie staining or analysis by
estern blotting using a monoclonal mouse IgG antibody raised
gainst nhSP-A. rfhSP-A identity and purity was conﬁrmed by mass
pectrometry using previously described methods (Simon et al.,
016).
.5. Gel permeation chromatography
The quaternary structure of rfhSP-A was characterised by gel
ermeation chromatography using an Äkta 900 system (Amersham
ioSciences) with a 24 ml  Superdex 200 HR 10/30 column, equi-
ibrated in TBS with 5 mM EDTA, pH 7.4 (TBSE). The quaternary
tructure of rfhSP-A was estimated through comparison with elu-
ion positions of molecular weight standards kit (Sigma-Aldrich).
imeric rfhSP-A was puriﬁed by gel permeation chromatography,
s above but using a preparative 90 ml  Superdex 200 column.
.6. Puriﬁcation of functional mannan binding rfhSP-A
Functional rfhSP-A was puriﬁed by afﬁnity chromatography
sing a 15 ml  mannan-coupled sepharose column. The afﬁnity col-
mn  was equilibrated in 20 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH
.4 (TBSC). rfhSP-A was then injected onto the column using an Äkta
00 system. The column was washed in 20 mM Tris, 1 M NaCl, 5 mM
aCl2, pH 7.4, after which it was re-equilibrated in TBSC. Functional
fhSP-A was eluted in TBSE.
.7. Solid-phase mannan binding assay
Maxisorp plates were coated with 100 l of mannan (50 g/ml)
n 0.1 M NaHCO3 pH 9.6 at 4 ◦C overnight. Plates were washed 4
imes with TBS with 0.05% Tween (v/v) and blocked in TBS with
% BSA (w/v) (block buffer) for 6 h at 37 ◦C. Protein was incu-
ated at varying concentrations in either TBSC or TBSE at 4 ◦C
vernight with subsequent washing in either TBSC or TBSE 4 times.
inding was detected using a polyclonal rabbit anti-nhSP-A IgG
rimary antibody and a goat anti-rabbit IgG HRP conjugated sec-
ndary antibody diluted in block buffer, with either 5 mM  CaCl2 or
 mM EDTA as appropriate. Wells were washed in either TBSC or
BSE 4 times, as above. SP-A binding was detected by addition of
,3′,5,5′-tetramethylbenzidine (TMB) reagent mix  with subsequent
nhibition of reaction after 15 mins with 0.5 M H2SO4. Absorbance
as measured at  = 450 nm.
.8. Infection of bronchial epithelial cells with RSV
Human bronchial epithelial cells (AALEB), immortalised through
peciﬁc transfection with the simian virus 40 early region and
he telomerase catalytic subunit hTERT, were used in infection
ssays and have previously been described (Lundberg et al., 2002).
ALEB cells were grown in Bronchial Epithelial Growth Medium
BEBM plus SingleQuots of Growth Supplements) (Lonza). AALEB
ells were grown to 80% conﬂuency in 24 well plates coated with
ollagen. AALEB cells were serum starved for 24 h in BEBM supple-
ented with ITS 1X (insulin, transferrin, selenium, Thermo Fisher
cientiﬁc) and 0.02% BSA (Sigma-Aldrich) and infected with a clin-
cally relevant RSV-A (Memphis 37) strain, originally isolated by
eVincenzo et al. (DeVincenzo et al., 2010). Cells were infected
ith either a low (multiplicity of infection (MOI) of 0.08) or highMOI of 0.4) dose of RSV diluted in DMEM (4 mM l-glutamine). RSV
as preincubated with varying concentrations of nhSP-A, rfhSP-
, dimeric rfhSP-A or BSA diluted in DMEM (4 mM l-glutamine).
ells were infected for 2 h, after which they were washed and leftgy 222 (2017) 111–118 113
for 24 h in BEGM media without serum but with recommended
supplements.
2.9. Quantifying RSV infection by RT-qPCR
RNA was harvested from cells infected at an MOI  of 0.08 using
peqGOLD TriFast (Peqlab, Germany), according to manufacturer’s
instructions. Reverse transcription was performed using a High-
Capacity cDNA Reverse Transcription Kit (Life Technologies) with
random primers according to manufacturer’s instructions. RSV N
gene expression was  analysed using TaqMan Universal PCR Mas-
ter Mix  (No AmpErase UNG reagent) with an Applied Biosystems
7900HT Fast Real-Time PCR System machine (all from Life Tech-
nologies). Gene expression was normalised against expression of
Hypoxanthine Phosphoribosyltransferase 1 (HPRT) using the 2−Ct
method. Average relative percentage infection was then calculated
by normalisation as a percentage against the RSV untreated control.
2.10. Flow cytometry
Cells infected with an MOI  of 0.4 were detached from wells
using trypsin-EDTA (Sigma-Aldrich), washed in PBS and ﬁxed in
Cytoﬁx/Cytoperm (BD Biosciences) at 4 ◦C for 20 min. Infected cells
were identiﬁed using a mouse anti-RSV-F protein IgG primary anti-
body (Ambsio: C01626M) and a goat anti-mouse IgG antibody
conjugated with Alexa-Fluor 488 secondary (Invitrogen: A11001)
diluted in Perm/Wash (BD Biosciences). Cells were analysed using
a FACSAria cell sorter (BD Biosciences). Cells were regarded as
infected if above the ﬂuorescence threshold, which was set to
approximately 1% of the uninfected control. Average relative per-
centage infection was calculated as above.
2.11. Statistical analysis
An unpaired two-tailed Student’s t-test with equal variance was
used to calculate differences of RSV infection by treatment with
protein. To calculate signiﬁcant differences between treatments, a
two-way ANOVA with multiple comparisons was used corrected
using the Bonferroni method. Results were regarded as statistically
signiﬁcant at p < 0.05.
3. Results
3.1. The NT tag allows high levels of rfhSP-A expression and
puriﬁcation
To produce a recombinant trimeric fragment of human SP-A, E.
coli bacteria were initially inoculated with the expression plasmid
containing the 8x Gly Xaa Yaa triplets, neck and CRD of human
Sftpa1. However, upon induction, the rfhSP-A protein was  not
expressed at detectable levels (Fig. 1). Different expression temper-
atures, times and IPTG concentrations did not improve expression,
which could only be detected by overexposure of a western blot
(Supplementary Fig. 2). Implementation of the novel expression
tag NT, however, overcame this problem and allowed high levels
of expression of an NT and rfhSP-A fusion protein (NT-rfhSP-A)
(Fig. 1). NT-rfhSP-A was  expressed in inclusion bodies as indi-
cated by the analysis of soluble and insoluble fractions. Inclusion
bodies containing NT-rfhSP-A were washed and NT-rfhSP-A was
solubilised using 8 M urea, with subsequent refolding (Fig. 2A). The
refolded NT-rfhSP-A was puriﬁed effectively using nickel afﬁnity
chromatography with subsequent removal of the NT tag. This led
to the generation of pure rfhSP-A with no NT tag contamination
(Fig. 2B).
114 A. Watson et al. / Immunobiology 222 (2017) 111–118
Fig. 1. rfhSP-A expression with and without the NT solubility tag. rfhSP-A and NT-rfhSP-A expression was induced using 0.5 mM IPTG overnight at 30 ◦C. Expression was
analysed by SDS-PAGE under reducing conditions with subsequent (A) Coomassie staining or (B) Western blotting analysis using an antibody raised against SP-A. Indicated
are  the bacterial samples before induction (rfhSP-A and NT-rfhSP-A) and post induction (rfhSP-A I and NT-rfhSP-A I). nhSP-A was also included as a positive control for
comparison with Western blotting.
Fig. 2. NT-rfhSP-A is expressed as an insoluble protein but allows isolation of pure rfhSP-A. Puriﬁcation samples were analysed by SDS-PAGE with subsequent Coomassie
staining. (A) NT-rfhSP-A was  expressed in inclusion bodies as indicated by the analysis of soluble and insoluble fraction of cell lysate after increasing numbers of washes
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T-rfhSP-A (rfhSP-A).
.2. The rfhSP-A sequence is sufﬁcient to form carbohydrate
inding trimeric units
Puriﬁed rfhSP-A was analysed using gel permeation chromatog-
aphy (Fig. 3A). 72% of the puriﬁed rfhSP-A was trimeric, with 15%
eing dimeric and 9% being monomeric protein, highlighting that
he CRD, neck and 8x Gly Xaa Yaa sequence of human SP-A is sufﬁ-
ient to form trimeric units. A proportion of rfhSP-A was functional
nd bound to a mannan coupled afﬁnity column in a calcium-
ependent manner; use of carbohydrate afﬁnity chromatography
hus allowed functional carbohydrate binding protein to be puriﬁed
Fig. 3B). The rfhSP-A puriﬁed by mannan afﬁnity chromatography
as trimeric (Fig. 3C) and of high purity as assessed by SDS-PAGEFig. 3D), Western blotting (Fig. 3E) and mass spectrometry (data
ot shown). The trimeric structure was stable upon further analysis
y gel permeation chromatography after freeze/thawing. Dimeric
fhSP-A was likewise puriﬁed by gel permeation chromatographyation and subsequent refolding (refolded), ﬂow through of the nickel column (FT),
avage of target fusion protein (Cleaved) and puriﬁcation of rfhSP-A from cleaved
for comparison, and did not bind to a mannan coupled afﬁnity col-
umn  (Supplementary Fig. 3). Comparatively, puriﬁed nhSP-A was  of
higher order oligomeric structure with an apparent weight of >669
kDa as compared to molecular weight standards (data not shown).
The capacity of carbohydrate afﬁnity puriﬁed trimeric rfhSP-A to
bind to mannan was conﬁrmed using a mannan solid-phase binding
assay (Fig. 4A). Trimeric rfhSP-A bound to mannan in a calcium-
dependent manner. This binding was  speciﬁc to the mannan coated
onto the plates and was inhibited by the presence of soluble man-
nan (Fig. 4B); nhSP-A also bound mannan coated plates in a calcium
dependent manner (data not shown).
3.3. rfhSP-A is highly efﬁcacious at neutralising RSVThe capacity of trimeric rfhSP-A to neutralise RSV and prevent
infection of differentiated human bronchial epithelial (AALEB) cells
was compared with nhSP-A at a low dose of RSV (MOI of 0.08). RSV
A. Watson et al. / Immunobiology 222 (2017) 111–118 115
Fig. 3. Puriﬁcation of functional trimeric rfhSP-A. (A) rfhSP-A was  analysed by gel permeation chromatography. Elution of protein was  detected by measuring optical
absorbance at  = 280 nm.  Indicated are the elution volumes of molecular weight standards: apoferritin 443 kDa; alcohol dehydrogenase 150 kDa; bovine serum albumin
66  kDa, carbonic anhydrase 29 kDa and cytochrome C 12 kDa. rfhSP-A is mainly trimeric and the trimer eluted from the column at 13.8 ml (expected molecular weight of
trimer,  57 kDa). (B) Functional rfhSP-A was puriﬁed by mannan afﬁnity chromatography. rfhSP-A was eluted from the mannan afﬁnity column after washing in 1 M NaCl
with  5 mM CaCl2 using TBS with 5 mM EDTA. (C) Functional rfhSP-A puriﬁed by mannan afﬁnity chromatography was analysed by gel permeation chromatography as above.
Puriﬁed functional rfhSP-A was  assessed by SDS-PAGE under reducing conditions with (D) Coomassie staining and (E) Western blotting analysis using an antibody raised
against nhSP-A.
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sig. 4. Conﬁrmation of trimeric rfhSP-A being functional in binding to mannan. (A) 
f  calcium or EDTA. Binding was detected using an antibody raised against nhSP-A
fhSP-A in the presence of calcium with increasing amounts of soluble mannan. Dis
NA was quantiﬁed by RT-qPCR at 24 h after infection (Fig. 5A). Pre-
ncubation of RSV with nhSP-A reduced RSV infection by a mean
±SD) of 14.5 (±21.6) % (not signiﬁcant (n.s)) at 1 g/ml and sig-
iﬁcantly by 30.0 (±22.8) % (p < 0.05) at 5 g/ml. Comparatively,
re-treatment with trimeric rfhSP-A signiﬁcantly reduced infec-
ion in a dose-dependent manner by 54.9 (±9.0) % (p < 0.01) and
3.7 (±22.2) % (p < 0.001) at 1 g/ml and 5 g/ml, respectively. Pre-
reatment of RSV with 5 g/ml of BSA did not reduce infection
evels.
To conﬁrm the functionality of trimeric rfhSP-A and its capac-
ty to neutralise RSV, AALEB cells were infected using a higher
ose of RSV (MOI of 0.4) and virus presence was detected using
ow cytometry (Fig. 5B). Bronchial epithelial cells were gated by
ize and width (Supplementary Fig. 4A) and were infected in as concentrations of rfhSP-A were applied to mannan coated plates in the presence
peciﬁcity of binding to mannan was conﬁrmed by addition of 5 g/ml of trimeric
d are mean ± SD of 3 experiments.
dose dependent manner with increasing titres of virus. An MOI
of 0.4 resulted in ∼30–35% of cells being detected as infected as
determined by ﬂow cytometry; only background levels of infection
were detected upon infection with UV treated RSV (Supplemen-
tary Fig. 4). Pre-incubation with nhSP-A reduced RSV infection by a
mean (±SD) of 24.7 (±27.2) % at 0.2 g/ml (n.s) and signiﬁcantly by
38.5 (±28.4) % and 24.7 (±29.6) % at 1 g/ml and 5 g/ml, respec-
tively (p < 0.05) (Fig. 5B). Trimeric rfhSP-A signiﬁcantly reduced RSV
infection in a dose-dependent manner by 39.8 (±6.8), 85.9 (±4.2)
and 96.4 (±1.9) % at 0.2 g/ml 1 g/ml and 5 g/ml, respectively
(p < 0.001, p < 0.001 and p < 0.0001, respectively). Importantly, at
5 g/ml trimeric rfhSP-A reduced relative infection levels to only
3.7 (±2.2) % (p < 0.0001), thus reaching base line levels in uninfected
controls (2.5 (±0.2) % (p = 0.2)). Dimeric rfhSP-A also reduced RSV
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Fig. 5. Trimeric rfhSP-A reduces RSV infection of human bronchial epithelial cells.
(A)  RSV N gene expression was quantiﬁed using RT-qPCR in human bronchial epithe-
lial  (AALEB) cells infected with a low dose of RSV (MOI of 0.08). Prior to infection,
RSV was incubated for 1 h at 37 ◦C either alone or with 1 g/ml or 5 g/ml of nhSP-
A  or trimeric rfhSP-A or 5 g/ml of bovine serum albumin. (B) Infection levels of
AALEB cells infected with a higher dose of RSV (MOI of 0.4) were quantiﬁed by ﬂow
cytometry using an antibody raised against RSV F protein. Prior to infection, RSV
was  incubated for 1 h at 37 ◦C either alone or with 0.2 g/ml, 1 g/ml or 5 g/ml of
nhSP-A, trimeric rfhSP-A, dimeric rfhSP-A or BSA. Shown is the mean (±SD) of at
least  3 experiments undertaken in duplicate. Indicated are signiﬁcant differences
between untreated and treated virus (calculated using unpaired two tailed Stu-
dent’s t-test with equal variance) (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
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and signiﬁcant differences between treatments (calculated using two-way ANOVA
ith multiple comparisons corrected using the Bonferroni method) (# p < 0.05, ##
 < 0.01, ### p < 0.001, #### p < 0.0001).
nfection to some degree by 34.3 (±20.5) %, 43.2 (±24.5) % and 34
±16.1) % at 0.2 g/ml, 1 g/ml and 5 g/ml, respectively (p < 0.05,
 < 0.05 and p < 0.01, respectively). However, trimeric rfhSP-A was
igniﬁcantly more effective at reducing RSV infection at 1 g/ml
nd 5 g/ml than dimeric rfhSP-A (p < 0.001 and p < 0.0001, respec-
ively). Contrasting to pretreatment of RSV with nhSP-A, trimeric
nd dimeric rfhSP-A, pre-incubation with 5 g/ml of BSA did not
educe infection levels.
. Discussion
SP-A has been shown to interact with and neutralise RSV in vivo.
owever, the importance of the human SP-A oligomeric structure
n its interaction with RSV has not previously been determined. We
ave introduced a novel expression system to overcome previous
echnical issues to generate for the ﬁrst time a functional trimeric
fhSP-A molecule and demonstrated its efﬁcacy in neutralising RSV.
.1. Production of a functional trimeric rfhSP-A molecule using a
ovel expression tag (NT)The generation of recombinant versions of SP-A has been impor-
ant in delineating the anti-pathogenic and immunomodulatory
unctions of SP-A (Wright, 2005). Recombinant SP-A may  have ther-
peutic potential, particularly as an adjunct treatment to currentgy 222 (2017) 111–118
lipid surfactants alongside recombinant SP-D. These recombinant
collectins could replace the deﬁcient immunomodulatory host pro-
teins SP-A and SP-D in the premature neonatal lung and prevent
the development of neonatal chronic lung disease with associated
respiratory and neurological complications (Clark, 2010). Recom-
binant SP-A and SP-D may  also have potential as novel adjunctive
synthetic anti-inﬂammatory and anti-infective agents in other dis-
ease settings including severe asthma and COPD (Clark, 2010;
Mackay et al., 2016).
Previous studies have produced full-length recombinant human
SP-A molecules (Head et al., 2003; Garcia-Verdugo et al., 2003).
However, problems with full length SP-A have been found with
regards to self-aggregation mediated through the collagen-like
domain and higher order oligomers (Haagsman et al., 1990). Full
length SP-A requires expression in eukaryotic systems, which is
expensive, and results in relatively low yields. A trimeric rfhSP-A
molecule which lacks the majority of the collagen domain and is
expressible in bacteria would overcome these issues.
One study reported an attempt to produce a truncated fragment
of human SP-A without the collagen stalk but did not demonstrate
the production of a functional trimeric fragment (Sotiriadis et al.,
2015). The inclusion of the 8x Gly Xaa Yaa collagen stalk in the
related rfhSP-D molecule, is thought to stabilise the trimeric struc-
ture, and has previously been shown to be essential for its function
in vivo (Knudsen et al., 2009). In addition, removal of the entire SP-A
collagen domain through collagenase digestion has previously been
shown to result in either purely monomeric subunits (Murata et al.,
1993) or a mixture of trimers and monomers, dependent on the
buffer salt concentration (Haagsman et al., 1989). A short collagen
stalk may  therefore be required for a functional trimeric rfhSP-A
molecule.
Previous attempts to express a trimeric rfhSP-A molecule
including the 8x Gly Xaa Yaa collagen stalk have not been success-
ful. This could be for various reasons, including potential difﬁculty
of translating the N-terminal part of the truncated protein or
the presence of numerous prolines, as found in rfhSP-A: this has
previously been reported to have a negative impact on elonga-
tion of protein translation in E. coli (Hersch et al., 2014). Through
implementing a novel E. coli expression strategy using a new het-
erologous expression tag, NT, we have overcome the issues of
expressing trimeric rfhSP-A with the collagen stalk and for the ﬁrst
time demonstrated the production of a functional trimeric rfhSP-A
molecule.
In nature, NT allows expression of large amounts of soluble
spidroins and has allowed expression of a very aggregation-prone
amyloidogenic protein (Hedhammar et al., 2008; Dolfe et al., 2016).
Using this expression tag, we  have expressed trimeric rfhSP-A at
high levels in a bacterial expression system. Importantly, compar-
ative to full length recombinant SP-A molecules, trimeric rfhSP-A
lacks the majority of the collagen domain and the N-terminal
domain and thus has a lower propensity to self-aggregate, and has
an increased solubility. The rfhSP-D of the closely related molecule
SP-D is a well characterised molecule and has provided a wealth of
information about the structure/function relationship of SP-D and
mode of calcium-dependent ligand binding (Clark et al., 2016, 2005,
2003; Clark, 2010; Strong et al., 2002; Lin et al., 2010; Knudsen et al.,
2007; Roona et al., 2012). Thus, this functional trimeric rfhSP-A
may  prove a useful reagent for research and has increased poten-
tial for development as a therapeutic as compared with full-length
recombinant SP-A.
4.2. Trimeric rfhSP-A lacking the N-terminal domain is highly
effective at neutralising RSV
In this present study, we  have demonstrated the capacity of both
nhSP-A and a functional trimeric rfhSP-A molecule to neutralise
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 clinically relevant strain of RSV in an in vitro human bronchial
pithelial cell model. This suggests that similarly to SP-D, the N-
erminal domain and entire collagen domain is not required for
eutralisation of RSV (Hickling et al., 1999).
Strikingly, trimeric rfhSP-A reduced RSV infection to levels near
o the uninfected control. Thus the N-terminal domain and major-
ty of the collagen domain is not essential for the capacity of SP-A
o neutralise RSV (Barr et al., 2000). nhSP-A has previously been
hown to neutralise RSV and reduce infection levels by 13.3% and
3.3% at a concentration of 10 g/ml and 20 g/ml, respectively
Ghildyal et al., 1999). In this present study, lower concentrations
f nhSP-A were used but the capacity for neutralisation was  not dis-
imilar with infection levels being reduced by up to 38.5 (±28.4) %
t 1 g/ml. nhSP-A signiﬁcantly reduced RSV infection compared
o both preincubation without protein or preincubation with a BSA
ontrol.
Trimeric rfhSP-A appeared to neutralise RSV more effectively
han oligomeric nhSP-A. This increased efﬁcacy could in part be
ue to the lower molecular weight of rfhSP-A and thus increased
umber of functional CRDs per microgram of protein. With the
olecular weight of a nhSP-A subunit being 26–38 kDa compar-
tive to the 19 kDa molecular weight of a rfhSP-A unit, there were
p to 2 fold more CRDs for each treatment with trimeric rfhSP-A
ompared with nhSP-A. However, this does not fully account for
he increased efﬁcacy of treatment with trimeric rfhSP-A particu-
arly upon infection with the higher dose of RSV (Fig. 5B). In this
tudy, nhSP-A was puriﬁed from patients with alveolar proteinosis
sing butanol extraction. Although this method has been widely
sed in the literature for purifying nhSP-A, functionality could be
mpacted by the speciﬁc patient from which the SP-A was  puriﬁed,
he absence of the lipid surfactant or the extraction method itself
Wright et al., 1987; Tino and Wright, 1999, 1996; McKenzie, 2015;
hitwell et al., 2016). However, nhSP-A used in this study was
onﬁrmed to be oligomeric and functional in binding to mannan.
Upon increasing the dose of nhSP-A from 1 to 5 g/ml, the lev-
ls of RSV neutralisation were not signiﬁcantly increased. This also
uggests that the increased efﬁcacy of trimeric rfhSP-A as com-
ared with nhSP-A is not solely a consequence of the number of
unctional CRDs in the assay. The apparent increased efﬁcacy of
hSP-A at neutralising the higher dose of RSV at a concentration of
 g/ml as compared with 5 g/ml is difﬁcult to explain but could
imply be due to 1 g/ml being a sufﬁcient dose to reduce RSV
nfection by the maximum amount; any slight difference between
 and 5 g/ml could be due to experimental variability. Alterna-
ively there could be dual mechanisms in play. SP-A has previously
een reported to be exploited by RSV in vitro and to provide a
oute of entry to enhance infection of Hep2 cells (Hickling et al.,
000). Thus, it is tempting to hypothesise that nhSP-A could work
n a dual manner to both neutralise RSV to some degree but also
nteract with putative receptors to provide a route of entry into the
ell, the balance of these two mechanisms could be highly depen-
ent on the concentration of nhSP-A. The N-terminal domain of
P-A is thought to interact with numerous receptors including the
alrecticulin/CD-91 complex and SPR-210 which are expressed on
lveolar epithelial cells and macrophages, reviewed in (Jakel et al.,
013). The increased capacity of trimeric rfhSP-A to neutralise RSV
s compared with nhSP-A may, therefore, be due to its capacity to
eutralise RSV whilst lacking the N-terminal domain with poten-
ial to interact with cellular receptors and bring the virus into close
roximity with potential sites for infection. The interaction of SP-A
ith putative receptors and its potential impact on RSV infection,
owever, remains to be fully characterised.
Dimeric rfhSP-A produced through a similar manner to func-
ional trimeric rfhSP-A also reduced RSV infection to some degree,
lthough this was signiﬁcantly less effective than trimeric rfhSP-
. Interestingly, a monomeric SP-A CRD plus neck fragment hasgy 222 (2017) 111–118 117
previously been shown to function in binding to alveolar type II cells
and inhibit phospholipid secretion, suggesting that the trimeric
structure with three correctly folded CRDs may not be essential
for some of the broad functionality of SP-A at least (Murata et al.,
1993).
In this present study, a homotrimeric fragment composed of
only SP-A1 was used. However, human SP-A has previously been
shown to be a mixture of SP-A1 and SP-A2 (Tagaram et al., 2007).
Importantly, functional differences between SP-A1 and SP-A2 have
been found, including the capacity of SP-A2 to bind various sugars
with a higher afﬁnity than SP-A1 (Sanchez-Barbero et al., 2007;
Floros et al., 2009; Oberley and Snyder, 2003). Thus it would be
interesting to produce a functional trimeric rfhSP-A from SP-A2 and
compare its efﬁcacy in neutralising RSV with the trimeric rfhSP-A
of SP-A1 used in this study.
The importance of nhSP-A during RSV infection in an in vivo
setting is likely different to in vitro due to the presence of lipid
surfactant, immune cells including macrophages and T cells, other
defence molecules and cytokines. nhSP-A likely has an important
role in agglutination of RSV and, as previously suggested, may  have
a role in clearance by macrophages (LeVine et al., 1999). Further
work comparing the capacity of trimeric rfhSP-A to prevent infec-
tion, enhance clearance by macrophages and reduce inﬂammatory
pathogenesis in murine models of RSV infection is now needed.
5. Conclusion
We have for the ﬁrst time implemented a novel expression tag to
generate and successfully express a trimeric recombinant fragment
of human SP-A; this tag may have general utility for expression
of other heterologous protiens. Moreover, we have shown this
trimeric rfhSP-A, to be highly efﬁcacious at neutralising a clini-
cally relevant strain of RSV in an in vitro model of human bronchial
epithelial cells.
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